What's Going On With NLS Pharmaceutics Shares Monday?
What To Know: In addition to the
Specifically, the funding will support Kadimastem’s Phase IIa multi-site clinical trial for Amyotrophic Lateral Sclerosis using AstroRx and Phase I trial for IsletRx in type 1 diabetes patients.
“We are pleased to have secured this capital on favorable terms, which reflects investor confidence in our vision and the transformative potential of our planned merger with Kadimastem,” said
“We believe that with these financial resources in place, we are well-positioned to move forward with completing the transaction and creating a leading company in the field of regenerative medicine and CNS disorders.”
See Also: Palatin Technologies’ Obesity Drug Co-Administered With Eli Lilly’s Blockbuster Drug Shows 4.4% Reduction In Weight
NLSP Price Action: At the time of writing,
Image: via Shutterstock
close
What's Going On With NLS Pharmaceutics Shares Monday?
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
Japan's Mitsubishi may consider investing in Alaska LNG project, CEO says
Reuters - 27 minutes ago
-
Tencent-backed China Ruyi aims to raise up to $500 million in convertible bonds, sources say
Reuters - 30 minutes ago
-
Ryan Gosling, Halle Berry and more pitch Amazon's deep dive into movies
Reuters - 35 minutes ago
-
Pinduoduo to invest $13.7 billion to transform, upgrade merchants
Reuters - 38 minutes ago
-
World leaders condemn Trump's tariffs, some pledge retaliation
Reuters - 39 minutes ago
-
Novo Nordisk's head of commercial strategy steps down
Reuters - 50 minutes ago
-
DHL sees EBIT growth in mail and parcel division after 2030
Reuters - 51 minutes ago
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
